• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Cobimetinib

CAS No. 934660-93-2

Cobimetinib ( GDC-0973 | XL-518 | GDC 0973 | XL 518 | GDC0973 | XL518 )

产品货号. M16682 CAS No. 934660-93-2

Cobimetinib (GDC-0973, XL-518) 是一种有效的选择性 MEK 抑制剂,对 MEK1 的 IC50 为 4.2 nM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥392 有现货
5MG ¥757 有现货
10MG ¥945 有现货
25MG ¥1730 有现货
50MG ¥3041 有现货
100MG ¥4257 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥885 有现货

生物学信息

  • 产品名称
    Cobimetinib
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Cobimetinib (GDC-0973, XL-518) 是一种有效的选择性 MEK 抑制剂,对 MEK1 的 IC50 为 4.2 nM。
  • 产品描述
    Cobimetinib (GDC-0973, XL-518) is a potent, selective MEK inhibitor with IC50 of 4.2 nM for MEK1; shows excellent selectivity against mTOR, DNA-dependent protein kinase (DNA-PK), and a panel of more than 228 kinases; shows strong cellular potency in a broad panel of tumor types, particularly in BRAF or KRAS mutant cancer cell lines, triggers robust apoptosis and tumor growth inhibition in vivo combined with PI3K inhibitor GDC-0941.Skin Cancer Approved(In Vitro):The EC50 values of Cobimetinib (GDC-0973) for 888MEL and A2058 cells are 0.2 μM, 10 μM, respectivelly. Melanoma cells are treated with EC50 concentration of MEK and PI3K inhibitors for 24 hours (888MEL: 0.05 μM GDC-0973, 2.5 μM GDC-0941; A2058: 2.5 μM GDC-0973, 2.5 μM GDC-0941). Mitochondrial OXPHOS limits cell death induced by cobimetinib (100 nM) in melanoma with constitutive MAPK activation in A375 cells.(In Vivo):In the NCI-H2122 KRASG12C mutant non-small cell lung carcinoma (NSCLC) xenograft model, treatment with up to 5 mg/kg Cobimetinib (GDC-0973) lead to moderate TGI and at 10 mg/kg approaches tumor stasis. GDC-0973 and GDC-0941 are administered to A2058 tumor-bearing mice daily (QD) or every third day (Q3D) either as single agents or in combination. The population rate constants associated with tumor growth inhibition for GDC-0973 and GDC-0941 are 0.00102 and 0000651 μM-1 h-1, respectively. Following single doses of GDC-0973 (1, 3, or 10 mg/kg, p.o.) estimated in vivo IC50 values of %pERK decrease based on tumor concentrations in xenograft mice are 0.78 (WM-266-4) and 0.52 μM (A375).
  • 体外实验
    ——
  • 体内实验
    ——
  • 同义词
    GDC-0973 | XL-518 | GDC 0973 | XL 518 | GDC0973 | XL518
  • 通路
    MAPK/ERK Signaling
  • 靶点
    MEK
  • 受体
    MEK1
  • 研究领域
    Cancer
  • 适应症
    Skin Cancer

化学信息

  • CAS Number
    934660-93-2
  • 分子量
    531.31
  • 分子式
    C21H21F3IN3O2
  • 纯度
    >98% (HPLC)
  • 溶解度
    10 mM in DMSO
  • SMILES
    C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
  • 化学全称
    Methanone, [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]-

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Hoeflich KP, et al. Cancer Res. 2012 Jan 1;72(1):210-9. 2. Wong H, et al. Clin Cancer Res. 2012 Jun 1;18(11):3090-9. 3. Rice KD, et al. ACS Med Chem Lett. 2012 Apr 9;3(5):416-21. 4. Ribas A, et al. Lancet Oncol. 2014 Aug;15(9):954-65.
产品手册
关联产品
  • AZD8330

    AZD8330 (ARRY-424704;ARRY-704) 是一种有效的、选择性的、非 ATP 竞争性 MEK1/2 抑制剂,IC50 为 7 nM。

  • GNE-3511

    GNE-3511 是一种有效、选择性、口服生物利用度、脑渗透性双亮氨酸拉链激酶 (DLK、MAP3K12) 抑制剂,Ki 小于 0.5 nM。

  • QNZ46

    QNZ46 是一种 NR2C/NR2D 选择性 NMDA 受体非竞争性拮抗剂。